Close
Blog & Resources Camargo Blog September 7th, 2012

Court Dismisses K-V’s Suit Against FDA

Yesterday 9/6/2012, the U.S. District Court for the District of Columbia dismissed KV Pharmaceutical’s suit against the FDA. KV had asked the Court to force FDA to stop the marketing of compounded versions of 17-hydroxyprogesterone caproate cream and related imported API. FDA countered with the argument that the Courts cannot force the FDA to take action that is within its discretion. The Court sided with FDA.

An earlier post here documented KV’s plight – KV’s Makena wasn’t meeting the revenue required to keep the company in business, it filed bankruptcy and filed this suit in a last ditch attempt to satisfy its investors that everything possible had been done.

What appears to be the major problem is that KV did not correctly price the product and could not survive the firestorm of public criticism.

The discussion on compounding in the Court documents is interesting reading.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights